Loading…
Taiwan Liposome Company (TLC), a Taiwan biotech that reformulates drugs using proprietary liposome/lipid-based drug-delivery technology.
Taiwan Liposome Company (TLC), a Taiwan biotech that reformulates drugs using proprietary liposome/lipid-based drug-delivery technology.
In one line: A Taiwanese peer to Pacira BioSciences (liposomal drug reformulation).
Moat: narrow (IP / patents, process know-how). Proprietary liposome formulation technology used to extend or improve existing drugs, patent-protected.
Headquarters: Taipei, Taiwan · Founded: 1997
Size TLC BioSciences (7924.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $1.57B, the 196th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$388.00 on 6 Nov 2026.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| TLC BioSciences 7924.TWO | $1.57B | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% |
| Ipsen IPN.PA | $14.7B | -4% | +14% | 30% | 3.0× | -7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7924.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.0% | -6.5% | 5th lowest of 21 |
| Distance from 52-week high | -22.9% | -45.0% | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |